No abstract

The Leishmania donovani parasite causes visceral leishmaniasis (VL), an acute and fatal form of leishmaniasis. Because traditional therapy alternatives, such as glucantime and other pentavalent medicines, are toxic and have side effects, new treatments with fewer negative effects are needed. Only a handful of drugs are clinically beneficial to treatments of the disease, but considerable limitations threaten their very usage. Novel, safe, and efficient drugs, including those against antimalaria and leishmaniasis co-infections, are so essential. Artemether (ATM) is an Artemisinin derivative that has been demonstrated to be useful in the treatment of malaria and, more recently, leishmaniasis. The current research was carried out to evaluate the anti-leishmanial effects of Artemether (ART) and combination of Artemether- Artemisinin (ART- ATM) against procyclic promastigotes of Leishmania donovani. In this fundamental-applied research, we compared the effect of (ATM) and combination of (ART- ATM) on Leishmania donovani procyclic promastigotes, at different concentrations by using the MTT assay method after 24 ,48 and 72 h of treatment. The results prove ATM and combination (ART- ATM) efficiency against the procyclic promastigotes viability with IC50 measured after 24, 48- and 72hours treatment. The combination of (ART- ATM) could be used in the treatment of leishmaniasis to improve the therapeutic outcome for Leishmania species.

Cutaneous leishmaniasis (CL) is an endemic parasitic disease found in many provinces of Iraq. The immune system plays a crucial role in the development or healing of lesions through chemotactic cytokine activity. This study was aimed to detect the levels of two chemokine ligands (CCL2 and CCL5) in Iraqi patients suffering from dermal ulcers, caused by cutaneous leishmaniasis. It was measured in pre and post-treatment state of Pentostam (Pentavalent Antimony 100 mg). Blood serum concentrations of CCL2, CCL5 were measured by enzyme-linked immunosorbent assay among newly infected patients, two-trial treatment patients and three-trial treatment patients, in comparison with the control group. The result indicated a significant difference in CCL5 level for the three groups of CL patients. Whereas the control (p˂0.5), CCL2 level counterparts showed a significant difference only in newly infected and the thee-trial treatment groups. Moreover, there was a significant difference between all CCL5 patient groups, while no observed difference was detected within patient groups of CCL2.Thus altering the chemokine levels before and after treatment gives insights for parasite role in chemokine expression which may help in new therapeutic approaches for dry or wet CL.

Background: Cutaneous leishmaniasis (CL) is a neglected disease in tropical countries, including Iraq. Several studies have sought to examine chemotherapies for leishmaniasis treatment but most of them are of toxic and/or undesirable side effect, therefore, the need for investigating new fewer toxic therapies is essential. Aim of study: In this study, the cytotoxic effect of Artemisinin (ART), a novel herbal compound, was screened against the two forms, promastigotes and amastigotes, of the Iraqi isolate of Leishmania tropica, the causative agent of Baghdad boil. Material and methods:  Different concentrations (1000, 500, 250, 125, 62.5, 31.25, 15.6 and 7.8) µM of Artemisinin were screened to investigate the leishmanicidal activity of the herbal compound against the two forms of the parasite along three times of follow up (24, 48, 72) hour using MTT cytotoxicity assay. Results: The results showed that growth rate and cell viability were significantly decreased at all studied concentrations. The IC50 was measured after 72 hours of follow up and was 2.625 µM and 2.636 µM for promastigotes and amastigotes, respectively. Conclusion: These findings approved the leishmanicidal efficacy of Artemisinin against the of L. tropica and can be further studied to screen its effectiveness in vivo for exploring a safer herbal drug for treatment of cutaneous leishmaniasis.